| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Collegium Pharmaceutical, Inc.$34.03
-0.77 (-2.22%)
B 64Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.11 B
EPS
2.36
P/E Ratio
16.68 $
Value Trade
14.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
193.52 M
Operating CF
57.11 M
Total Assets
1.65 B
Total Liabilities
1.34 B
Equity
312.42 M
D/E Ratio
12,345
-2.29 %
Week
1.73 %
1 Month
-24.71 %
3 Month
-22.5 %
6 Month
38.44 %
5 Year
183.92 %
All Time
Cash Data
Cash Position
421.75 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
153.38 K
52 Week Range
28.74 - 50.79
% held by Insiders
1.95 %
% held by Institutions
122.48 %
Enterprise Value
1.59 B
Total Shares
32.42 M
Short %
18.62 %
Float Shares
30.41 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B64
Pipeline Score $5.6B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored15.0x
rNPV / MCap Top 92%
Micro Cap (rank 73 of 905)
Percentile RankCollegium Pharmaceutical, Inc. holds a solid B-grade pipeline (64/100), with $14.0B risk-adjusted pipeline value, led by Evolocumab in Sars-CoV-2 Infection (Phase 3), across $103B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evolocumab Small molecule | Sars-CoV-2 Infection | Phase 3 | NCT04941105 | 56% | $7.8B | COMPLETED | 60 | - | - | May 17, 2022 | - | Apr 21, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COLL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
COLL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COLL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COLL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COLL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
COLL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COLLCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical has announced the granting of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees as part of its 2026 Inducement Plan. This plan was adopted to comply with Nasdaq Listing Rule 5635(c)(4) and aims to enhance employee retention through a structured vesting schedule. The RSUs will vest over a three-year period, contingent on continued employment.
Read more →COLLCollegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The event will be available via a live webcast on the company's website, with a replay accessible for 90 days. Collegium focuses on innovative treatments for central nervous system and pain conditions.
Read more →COLLCollegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical, Inc. announced it will report its first quarter 2026 financial results on May 7, 2026, before market opening. Following the announcement, a live conference call and webcast will be held at 8:00 a.m. ET. The company is focused on enhancing its portfolio, particularly with its ADHD treatment, JORNAY PM.
Read more →COLLCollegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical, Inc. will present two posters featuring real-world data from its pain medication portfolio at PainConnect 2026. This event, hosted by the American Academy of Pain Medicine, will take place in Salt Lake City from March 5-8, 2026. The presentations aim to provide valuable insights into pain management practices.
Read more →COLLParis Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Collegium Pharmaceutical and Paris Hilton have launched the 'Embrace Your Sparkle' campaign to raise awareness about ADHD. The initiative aims to challenge stereotypes and promote open dialogue about the condition. Hilton shares her personal experiences with ADHD and emphasizes the importance of individualized treatment plans, highlighting her use of JORNAY PM for symptom management.
Read more →COLLCollegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. announced its participation in several upcoming investor conferences in Miami, Florida, scheduled from March 9 to March 11, 2026. The events include the Leerink Partners Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and Barclays 28th Annual Global Healthcare Conference. A live webcast of the fireside chat will be available on the company's website.
Read more →COLLCollegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2025, with net revenues reaching $205.4 million for the quarter and $780.6 million for the year. The company's Jornay PM product saw significant growth, contributing to a 48% increase in full-year revenue. Collegium's pain portfolio also performed well, and the company reaffirmed its guidance for 2026, indicating a positive outlook for continued growth.
Read more →COLLCollegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium Pharmaceutical, Inc. will report its fourth quarter and full-year 2025 financial results on February 26, 2026. The announcement includes details about a live conference call and webcast scheduled for 8:00 a.m. ET on the same day. The company aims to enhance its portfolio, focusing on pain management and ADHD treatments.
Read more →COLLCollegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Collegium Pharmaceutical announced it will present four posters featuring real-world data on its ADHD treatment, Jornay PM, at the APSARD Annual Conference in San Diego. The presentations aim to provide valuable insights for clinicians and the ADHD community. The conference will take place from January 15-18, 2026, with the poster session scheduled for January 17.
Read more →COLLCollegium Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical has successfully closed a $980 million syndicated credit facility, which includes a $580 million initial term loan and additional funding options. This facility is expected to enhance the company's financial outlook and provide flexibility for future business development. The initial loan will pay off a previous term loan, resulting in significant interest savings.
Read more →COLLCollegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Collegium Pharmaceutical reported strong financial results for Q3 2025, achieving record net revenue of $209.4 million, a 31% increase from the previous year. The company's Jornay PM product saw significant growth, contributing to the overall revenue increase. Additionally, Collegium raised its full-year guidance for net revenue to between $775 and $785 million, reflecting confidence in continued growth.
Read more →COLLParis Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
Collegium Pharmaceutical collaborates with Paris Hilton to share her ADHD journey, aiming to reduce stigma and encourage others to seek treatment. Hilton discusses her diagnosis and treatment with JORNAY PM, a CNS stimulant. The initiative highlights the importance of awareness during ADHD Awareness Month.
Read more →COLLCollegium to Report Third Quarter 2025 Financial Results on November 6, 2025
Collegium Pharmaceutical, Inc. will report its third quarter 2025 financial results on November 6, 2025, before market opening. Following the release, a live conference call and webcast will occur at 8:00 a.m. ET. The company aims to enhance its portfolio, focusing on responsible pain management and ADHD treatments.
Read more →COLLCollegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
Collegium Pharmaceutical announced poster presentations at the AACAP and NEI conferences, showcasing real-world data on Jornay PM, a CNS stimulant for ADHD. The presentations aim to provide insights into Jornay PM's use and reinforce the company's commitment to improving ADHD care. The conferences will take place in Chicago and Colorado Springs later this year.
Read more →COLLCollegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary on October 14, 2025, by ringing the Nasdaq opening bell. The company has made significant strides in responsible pain management and has expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD. This milestone highlights their commitment to improving patient lives and their growth trajectory in the healthcare sector.
Read more →COLLCollegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
Collegium Pharmaceutical, Inc. will showcase nine posters featuring real-world data from its pain management portfolio at PAINWeek 2025 in Las Vegas. The presentations aim to enhance clinical decision-making by providing healthcare professionals with valuable insights. This initiative reflects Collegium's ongoing commitment to responsible pain management.
Read more →COLLCollegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
Collegium Pharmaceutical reported a strong second quarter for 2025, achieving record net revenue of $188 million, a 29% increase year-over-year. The company also raised its full-year revenue guidance to between $745 and $760 million, driven by robust sales from its pain portfolio and Jornay PM. The CEO expressed optimism for continued growth in the second half of the year.
Read more →Competitive Position
How COLL ranks across every disease it competes inCompetitive Position is a premium feature
See how COLL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial